Study Details

Back to Search Results

A study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients with Anemia

This trial is complete
The study has ended normally, and participants are no longer being examined or treated (that is, the last participant's last visit has occurred).

Clinicaltrials.gov ID

The unique identification code given to each clinical study upon registration at ClinicalTrials.gov.
NCT02988973

Astellas Study ID

The unique identification code given by the study sponsor.

1517-CL-0310

EudraCT ID

The unique identification code given to each clinical study upon registration at EudraCT (European Union Drug Regulating Authorities Clinical Trials Database).

N/A

Follow Trial

Condition

Kidney Disease

Phase

These clinical trials are done to confirm that an experimental treatment helps participants who have a specific condition. These clinical trials often compare the experimental treatment to another treatment or, if appropriate, a placebo.

Phase 3

Age

20 years - N/A

Sex

Female & Male

Product

roxadustat

Type

A type of clinical study in which participants are assigned to groups that receive one or more intervention/treatment (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

Interventional

Trial Dates

Jan 2017 - Mar 2020

Masking

None (Open Label)

Enrollment number

334

A phase 3 multi-center, randomized, open-label, active-comparator (darbepoetin alfa) conversion study of intermittent oral dosing of ASP1517 in non-dialysis chronic kidney disease patients with anemia

Study summary

Study documents

Study Documents, including study results, are available after a study is completed or terminated, according to Astellas Transparency policy.

Get More Information

Would you like more information about clinical trial sites that are recruiting participants for A study of Intermittent Oral Dosing of ASP1517 in Non-Dialysis Chronic Kidney Disease Patients with Anemia? Contact us by filling our your information to the right and we’ll respond to you.

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

Locations

Site JP00049

Aasahikawa, Japan

Site JP00070

Hachioji, Japan

Site JP00024

Minato-ku, Japan

Site JP00010

Toyama, Japan

Site JP00038

Matsuyama, Japan

Site JP00026

Niigata, Japan

Site JP00068

Nagano, Japan

Site JP00001

Kamakura, Japan

Site JP00064

Sapporo, Japan

Site JP00022

Amagasaki, Japan

Site JP00012

Sendai, Japan

Site JP00014

Fukui, Japan

Site JP00030

Nagoya, Japan

Site JP00015

Koto-ku, Japan

Site JP00011

Sakai, Japan

Site JP00047

Fujisawa, Japan

Site JP00056

Osaka, Japan

Site JP00060

Ota-ku, Japan

Site JP00037

Hatsukaichi, Japan

Site JP00066

Nishinomiya, Japan

Site JP00045

Kyoto, Japan

Site JP00019

Toride, Japan

Site JP00069

Yao, Japan

Site JP00042

Kurume, Japan

Site JP00054

Tsukushino, Japan

Site JP00008

Kitakyusyu, Japan

Site JP00023

Sashima-gun, Japan

Site JP00003

Sakura, Japan

Site JP00039

Hiroshima, Japan

Site JP00058

Fukuoka, Japan

Site JP00063

Chiyoda-ku, Japan

Site JP00028

Koga, Japan

Site JP00041

Tajimi, Japan

Site JP00067

Hino, Japan

Site JP00009

Kasugai, Japan

Site JP00004

Koshigaya, Japan

Site JP00034

Oita, Japan

Site JP00062

Tachikawa, Japan

Site JP00033

Fukuoka, Japan

Site JP00002

Maebashi, Japan

Site JP00044

Matsuyama, Japan

Site JP00025

Adachi-ku, Japan

Site JP00061

Osaka, Japan

Site JP00021

Toyohashi, Japan

Site JP00032

Hiroshima, Japan

Site JP00005

Izumisano, Japan

Site JP00046

Tsuchiura, Japan

Site JP00055

Okayama, Japan

Site JP00050

Kure, Japan

Site JP00006

Musashino, Japan

Site JP00013

Kitakyusyu, Japan

Site JP00053

Naka, Japan

Site JP00035

Kanazawa, Japan

Site JP00016

Yokohama, Japan

Site JP00057

Kitakyusyu, Japan

Site JP00031

Morioka, Japan

Site JP00065

Fukuoka, Japan

Site JP00051

Nagoya, Japan

Site JP00052

Hitachi, Japan

Site JP00027

Suita, Japan

Site JP00040

Kitakyusyu, Japan

Site JP00059

Higashiosaka, Japan

Site JP00018

Nagano, Japan

Site JP00017

Kasama, Japan

Site JP00007

Sapporo, Japan

Site JP00020

Koshigaya, Japan

Site JP00071

Kagoshima, Japan

Site JP00029

Ageo, Japan

Site JP00043

Bunkyo-ku, Japan

Site JP00036

Ueda, Japan

Site JP00048

Yokohama, Japan

The purpose of this website is to offer education and information to patients and their families and friends, the public, and healthcare professionals about the clinical trial process. In addition, the website will provide specific information about Astellas clinical trials. Please read the complete Astellas Transparency Policy to learn about the clinical trial information available on this website

© ASTELLAS PHARMA GLOBAL DEVELOPMENT, INC.

POWERED BY:

Pharma Intelligence logo